| 3.86 0.09 (2.39%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.84 | 1-year : | 6.78 |
| Resists | First : | 5 | Second : | 5.8 |
| Pivot price | 4.15  |
|||
| Supports | First : | 3.69 | Second : | 3.07 |
| MAs | MA(5) : | 3.86 |
MA(20) : | 4.22 |
| MA(100) : | 4.38  |
MA(250) : | 4.54 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5.2 |
D(3) : | 5 |
| RSI | RSI(14): 42.4 |
|||
| 52-week | High : | 6.51 | Low : | 3.3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GDRX ] has closed above bottom band by 23.8%. Bollinger Bands are 9.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.9 - 3.92 | 3.92 - 3.94 |
| Low: | 3.68 - 3.71 | 3.71 - 3.74 |
| Close: | 3.82 - 3.86 | 3.86 - 3.9 |
GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was incorporated in 2015 and is headquartered in Santa Monica, California.
Tue, 21 Oct 2025
GoodRx Holdings, Inc. (GDRX) Stock Analysis: Exploring a 35% Upside Potential Amidst Healthcare Innovation - DirectorsTalk Interviews
Tue, 21 Oct 2025
GoodRx (GDRX): Buy, Sell, or Hold Post Q2 Earnings? - Yahoo Finance
Mon, 20 Oct 2025
GoodRx (GDRX): Evaluating Valuation as Shares Face Prolonged Slump in Healthcare Services Sector - Yahoo Finance
Tue, 14 Oct 2025
GoodRx Holdings, Inc. (GDRX) Stock Analysis: Unpacking a 29% Potential Upside for Savvy Investors - DirectorsTalk Interviews
Fri, 10 Oct 2025
GoodRx: Novo Deal And TrumpRx Talks Point To EBITDA/FCF Upside (NASDAQ:GDRX) - Seeking Alpha
Thu, 09 Oct 2025
GoodRx spikes after report on plans to join TrumpRx - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 99 (M) |
| Shares Float | 86 (M) |
| Held by Insiders | 12.6 (%) |
| Held by Institutions | 62.6 (%) |
| Shares Short | 6,270 (K) |
| Shares Short P.Month | 6,680 (K) |
| EPS | 0.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.84 |
| Profit Margin | 4.3 % |
| Operating Margin | 13.1 % |
| Return on Assets (ttm) | 5 % |
| Return on Equity (ttm) | 5.2 % |
| Qtrly Rev. Growth | 1.2 % |
| Gross Profit (p.s.) | 7.6 |
| Sales Per Share | 8.11 |
| EBITDA (p.s.) | 1.36 |
| Qtrly Earnings Growth | 102.4 % |
| Operating Cash Flow | 191 (M) |
| Levered Free Cash Flow | 124 (M) |
| PE Ratio | 42.88 |
| PEG Ratio | 0 |
| Price to Book value | 2.09 |
| Price to Sales | 0.47 |
| Price to Cash Flow | 1.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|